Back to Newsroom
Back to Newsroom

SHAREHOLDER ALERT: PS CVET SDC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Wednesday, 09 October 2019 08:35 PM

The Law Offices of Vincent Wong

Topic:
5

NEW YORK, NY / ACCESSWIRE / October 9, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Pluralsight, Inc. (NASDAQGS:PS)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/pluralsight-inc-loss-submission-form?prid=3888&wire=1
Lead Plaintiff Deadline: October 15, 2019
Class Period: August 2, 2018 to July 31, 2019

According to the filed complaint, the Company failed to disclose that Pluralsight was experiencing substantial delays in hiring and properly training the salesforce necessary to meet its lofty billing projections. In addition, the Company knew at the time of the March 2019 secondary public offering ("SPO") that it was behind schedule onboarding new sales representatives, which was hurting the Company's sales execution and preventing Pluralsight from meeting its high growth projections. Instead of disclosing such facts at the time of the SPO, and to cash-out at inflated prices, Defendants intentionally obscured and omitted this pertinent information from investors.

Covetrus, Inc. (NASDAQ:CVET)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/covetrus-inc-loss-submission-form?prid=3888&wire=1
Lead Plaintiff Deadline: November 29, 2019
Class Period: February 8, 2019 to August 12, 2019

Allegations against CVET include that: (i) the Company had overstated its capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein's Animal Health Business and VFC, including the timing and nature of those costs; (iii) Covetrus had understated its separation costs from Henry Schein; and (iv) the Company understated the impact on earnings from online competition and alternative distribution channels as well as the impact of the loss of a large customer in North America just prior to the Company's separation from Henry Schein.

Smiledirectclub, Inc. (NASDAQ:SDC)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/smiledirectclub-inc-loss-submission-form?prid=3888&wire=1
Lead Plaintiff Deadline: December 2, 2019
Class Period: on behalf of persons and entities that purchased or otherwise acquired SmileDirectClub Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's September 2019 initial public offering

Allegations against SDC include that: (1) administrative personnel, rather than licensed doctors, provided treatment to the Company's customers and monitored their progress; (2) as a result, the Company's practices did not qualify as teledentistry under applicable standards; (3) as a result, the Company was subject to regulatory scrutiny for the unlicensed practice of dentistry; (4) the efficacy of the Company's treatment was overstated; (5) the Company had concealed these deceptive marketing practices prior to the IPO; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong

Topic:
5
Back to newsroom
Back to Newsroom
Share by: